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Abstract: The oral administration of dapsone (DAP) for the treatment of cutaneous leishmaniasis 
(CL) is effective, although serious hematological side effects limit its use. In this study, we evaluated 
this drug for the topical treatment of CL. As efficacy depends on potency and skin penetration, we 
first determined its antileishmanial activity (IC50 = 100 μM) and selectivity index in vitro against 
Leishmania major-infected macrophages. In order to evaluate the skin penetration ex vivo, we 
compared an O/W cream containing DAP that had been micronized with a pluronic lecithin 
emulgel, in which the drug was solubilized with diethylene glycol monoethyl ether. For both 
formulations we obtained similar low flux values that increased when the stratum corneum and the 
epidermis were removed. In vivo efficacy studies performed on L. major-infected BALB/c mice 
revealed that treatment not only failed to cure the lesions but made their evolution and appearance 
worse. High plasma drug levels were detected and were concomitant with anemia and iron 
accumulation in the spleen. This side effect was correlated with a reduction of parasite burden in 
this organ. Our results evidenced that DAP in these formulations does not have an adequate safety 
index for use in the topical therapy of CL. 
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1. Introduction 
Leishmaniasis is a set of infectious diseases caused by intracellular protozoan parasites of the 
genus Leishmania. Over 12 million people are infected with leishmaniasis and about 1.2 million new 
cases appear annually [1]. There are three main clinical manifestations depending on the tissues and 
organs affected by the parasite: cutaneous, mucosal, or visceral leishmaniasis. Focusing on cutaneous 
leishmaniasis (CL), it causes localized skin lesions that may disappear without treatment or persist, 
causing severe tissue damage, permanent disfigurement, and serious disability. In general, species 
that are prevalent in the “old world” (i.e., Leishmania major and Leishmania tropica) produce limited 
clinical manifestations compared with “new world” species (i.e., Leishmania braziliensis, Leishmania 
amazonenesis, and Leishmania mexicana). 
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Currently, therapy for CL is based on the use of pentavalent antimonials, pentamidine, 
miltefosine, and amphotericin B (AmB). However, they have variable efficacy, serious side effects, 
high cost, and prolonged treatment that affects patient adherence. Additionally, parasite strains 
resistant to some of these treatments have led to failure of therapy in many cases. As these chemical 
approaches do not guarantee successful treatment of CL, the World Health Organization (WHO) 
recommends finding more effective oral or topical treatments with relatively less adverse effects [2]. 
In this context, topical treatments are desirable because of the lower systemic toxicity and costs, the 
ease of use and accessibility, and the higher patient compliance. Among the topical treatments, 
paromomycin (PM) has been the drug of choice for more than 50 years. Different formulations have 
been tested in patients with variable cure rates. A mixture of 15% PM plus 12% methylbenzethonium 
chloride was used to treat CL caused by L. braziliensis and L. mexicana, with cure rates around 80% 
[3]. Furthermore, L. major CL patients were treated with 15% PM or PM plus 0.5% gentamicin, with 
cure rates of 84% and 81%, respectively [4]. In a similar study of patients infected with Leishmania 
panamensis, 67% and a 94% of the lesions were healed after treatment with PM or PM plus gentamicin, 
respectively. Apart from the differences in efficacy depending on the Leishmania species, PM and its 
combinations also caused erythema, skin irritation, and pain [5].  
New topical products against CL not only have to exhibit intrinsic antileishmanial activity but 
also penetrate deeply into the dermis where the infected macrophages are and reside there long 
enough time to kill Leishmania parasites. Additionally, the capability of these products to modulate 
the immune system towards a bias that favors wound healing without scaring is needed [6].  
Dapsone (DAP, 4,4-diaminodiphenylsulfone, Table 1) is a sulfone derivative with a dual ability 
to act as an antimicrobial and anti-inflammatory agent. It was first used in the 1940s to treat leprosy. 
It was later introduced in the treatment of skin disorders such as acne or dermatitis herpetiformis [7]. 
Furthermore, its use as an antimalarial and antileishmanial drug has also been described. In 1986, 
Dogra et al. tried DAP treatment in Indian patients suffering from CL for the first time. A dose of 2 
mg/kg administered orally for 21 days produced 80% cure rate, and no relapses were declared after 
6 months [8]. In a double-blind study conducted in India, oral DAP was also used successfully in the 
treatment of CL. Here, 82% of the patients that received 100 mg DAP (approximately 4 mg/kg) twice-
daily for 6 weeks were cured at the end of treatment [9]. These results led to oral DAP being 
recommended as a first-line drug for CL in India. Recently, Indian children with CL lesions due to L. 
tropica were treated with oral DAP at a dose of 20 mg/kg per day for 4–6 weeks, with complete healing 
in 67% of patients. Moreover, the combination of DAP and rifampicin at the same dose produced a 
90% cure rate [10]. Despite its efficacy, its use by oral route is limited by its low water solubility, low 
bioavailability, and severe toxic effects, including hemolytic anemia and methemoglobinemia [11]. 
In recent years, topical DAP formulations have appeared as well-tolerated medications with 
mild side effects. A twice-daily 5% DAP gel demonstrated efficacy and safety in patients with acne 
vulgaris [12]. Additionally, a twice-daily 5% DAP gel was successfully used to treat papulopustular 
rosacea [13] and dermatitis herpetiformis [14]. However, topical DAP is approved only for treating 
acne vulgaris in some countries. 
Table 1. Physico-chemical properties of dapsone (DAP, 4,4-diaminodiphenylsulfone) of interest in 
topical delivery. 
 
DAP 
MW LogP Melting Point (°C) nON nOHNH 
248.3 0.94 175-176 4 4 
Abbreviations: MW, molecular weight; LogP, logarithm of compound partition coefficient between 
n-octanol and water; nON, number of hydrogen bond acceptors; nOHNH, number of hydrogen bond 
donors. 
Because oral DAP has shown efficacy in the treatment of CL lesions, and also because of its 
topical use in inflammatory skin diseases, we hypothesized that topical DAP could have a potential 
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therapeutic profile against CL. For this purpose, in vitro antileishmanial activity and cytotoxicity 
studies of DAP were carried out. Moreover, studies comparing the capacity of DAP to permeate and 
penetrate across pig ear skin formulated in a conventional O/W cream or in a pluronic-lecithin-based 
emulgel (PLE) were performed. Finally, the efficacy of a twice-daily topical DAP treatment in two in 
vivo models of CL due to L. major was determined. To the best of our knowledge, this is the first 
report evaluating the topical efficacy of this affordable and widely available drug against CL. 
2. Material and Methods 
2.1. Materials 
Dapsone (DAP), stearic acid, cetylic alcohol, glycerol monoestearate, solid paraffin, and white 
vaseline were supplied by Fagron (Terrassa, Spain). Liquid paraffin was obtained from Guinama (La 
Pobla de Valbona, Spain). Lipoid S100® (soybean lecithin) was kindly gifted by Lipoid GMBH 
(Ludwigshafen, Germany). Amphotericin B (AmB), ethylenediaminetetraacetic acid (EDTA), 
dimethyl sulphoxide (DMSO), sodium hydroxide, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT), methanol, phosphate buffered saline tablets, and Pluronic® F-127 were 
obtained from Sigma-Aldrich (St Louis, MO, USA). Miglyol 810® and Transcutol® were purchased by 
Gattefossé (Saint-Priest, France). Aldara® (IMQ 5%) was supplied by 3M Pharmaceuticals (St. Paul, 
MN, USA). Acetonitrile was provided by Merck (Germany). Water (>18 MΩ/cm resistivity) was 
obtained from an Ultramatic Type I system (Wasserlab, Spain). All other reagents were of analytical 
grade and were used without further purification.  
2.2. Parasites 
L. major (clone VI, MHOM/IL/80/Friendlin) and L. braziliensis (clone BA788) were maintained at 
26 °C and continuously stirred with M199 or Schneider’s modified medium (Sigma, St. Louis, Mo, 
Canada) supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Gibco, Gaithersburg, 
MD, USA) and 100 UI/mL of penicillin/streptomycin (Sigma) in flasks. M199 medium was 
supplemented with 25 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES, pH 7.2), 
0.1 mM adenine (Sigma), 0.0005% hemin (Sigma), 0.0001% biotin (Sigma), 10% heat-inactivated fetal 
calf serum (FCS, Gibco), and 100 UI/mL of penicillin/streptomycin. Procyclics were obtained after 1–
2 days culture and metacyclics were purified in the case of L. major from 5 to 6 days in stationary 
cultures by treatment with peanut agglutinin (PNA) (Sigma) in order to infect peritoneal 
macrophages and animals. In contrast, L. braziliensis metacyclics were not purified. Briefly, stationary 
promastigote cultures were washed twice in phosphate buffered saline (PBS, pH 7.4, Gibco), 
resuspended to 2 mL of simple Roswell Park Memorial Institute (RPMI) 1640 medium (Gibco, 
Gaithersburg, MD, USA), and incubated with 20 µg/mL of PNA (5 mg/mL in PBS) to purify 
metacyclics from L. major. After 20 min of incubation, 10 mL of RPMI 1640 was added carefully and 
the suspension was centrifuged (Allegra X-30 centrifuge, Beckman Coulter, Fullerton, CA, USA) at 
58× g for 5 min. The non-agglutinated promastigotes were collected from supernatants, washed two 
times in PBS, and used to infect macrophages or animals afterwards.  
2.3. Isolation of Mouse Peritoneal Macrophages and Cell Cultures 
To obtain mice peritoneal macrophages, BALB/c mice were inoculated with 1 mL of 3% (w/v) 
thioglycolate (Sigma). After 3 days, animals were euthanized and 5 mL of cold, simple RPMI 1640 
medium were injected into the peritoneal cavity and then recovered with a syringe. Cells were 
collected from the peritoneal fluid by centrifugation (Allegra X-30 centrifuge) at 524× g for 10 min. 
Then, the pellet was resuspended in RPMI 1640 supplemented with 10% FBS and 100 UI/mL of 
penicillin/streptomycin and incubated at 37 °C in 5% CO2.  
The 3T3 fibroflasts and HaCaT keratinocytes, obtained from the ATCC collection, were cultured 
in 5% CO2 at 37 °C in Dulbecco´s modified Eagle´s medium (DMEM, Gibco) containing 10% FBS, 2 
mM L-glutamine (Gibco), and 100 UI/mL of penicillin/streptomycin.  
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2.4. Animals 
The in vivo assays were carried out in female BALB/c mice (Harlan, Spain), weighing 
approximately 20 g. Animals were kept under conventional conditions with free access to food and 
water. Animals were housed in groups of five in plastic cages in controlled environmental conditions 
(12:12 h light/dark cycle and 22 ± 2 °C). This study was conducted according to ethical standards 
approved (21 October 2014, identification protocol code E15-18(126-14E6)) by the Animal Ethics 
Committee of the University of Navarra in strict accordance with the European legislation on animal 
experiments. 
2.5. In Vitro Activity Against L. major and L. braziliensis Promastigotes 
To determine the antileishmanial effect of DAP, MTT assays were carried out. Briefly, 2 × 105 
parasites per well were seeded in 96-well plates with different concentrations of DAP. Plates were 
then incubated at 26 °C for 48 h. After incubation, 20 µL of a MTT solution (5 mg/mL in PBS) was 
added to each well and plates were incubated at 26 °C for 4 h. Finally, 100 µL of DMSO was added 
and plates were gently shaken for 30 min to ensure complete solubilization of the formazan crystals. 
Parasite viability was determined using a microplate reader (iEMS Reader MS, Labsystems, 
Bradenton, FL, USA) at 570 nm. DAP was dissolved in DMSO and untreated cells were used as 
control. Wells containing only medium were included to subtract the medium background. Results 
are expressed as mean ± SD for at least three independent experiments in sextuplicate wells. Half-
maximum-effect substance concentration (EC50) values were obtained by fitting the data to a dose-
effect sigmoid curve using Prism 6.0 software (Graphpad Software Inc., San Diego, CA, USA). 
2.6. In Vitro Cytotoxicity in Peritoneal Macrophages, Fibroblasts, and Keratinocytes 
In vitro cytotoxicity assays were performed in mouse peritoneal macrophages, fibroblasts, and 
keratinocytes using MTT. Briefly, 2 × 105 peritoneal macrophages, fibroblasts, or keratinocytes were 
seeded in 96-well plates and incubated at 37 °C for 24 h. Then, different concentrations of DAP were 
added to wells and plates were again incubated for 48 h. Cells without drug treatment were used as 
control. After 48 h incubation, 20 µL of MTT (5 mg/mL) was added to wells and plates were incubated 
for 4 h. Then, 100 µL of DMSO was added after removing the medium from each well and plates 
were gently shaken for 30 min. Cell viability was determined using a microplate reader (iEMS Reader 
MS, Labsystems) at 570 nm. Results are expressed as EC50 mean ± SD for at least three independent 
experiments in sextuplicate wells.  
2.7. Effect of DAP on L. major and L. braziliensis Amastigotes  
Peritoneal macrophages of BALB/c mice were collected as described above. Macrophages in a 
concentration of 3 × 104 cells/well were seeded in Labtek plates (BD Biosciences, Franklin Lakes, IL, 
USA) and incubated at 37 °C with humidified atmosphere containing 5% CO2. After 24 h incubation, 
macrophages were washed twice with supplemented RPMI 1640 medium and infected with 
metacyclic promastigotes of L. major, isolated as previously described, at a ratio of 7:1 
(parasites/macrophages). For L. braziliensis infection, the infection rate was 10:1. Cells were incubated 
with parasites overnight at 37 °C and 5% CO2. Then, wells were washed at least three times with 
complete RPMI 1640 and treated with different concentrations of DAP (25–1000 M) for 48 h at 37 °C. 
AmB at 2 µM was used as positive control of treatment and was previously dissolved in DMSO. After 
48 h, wells were washed twice using PBS and then slides were fixed with cold methanol and stained 
with Giemsa for evaluation (Merck Darmstadt, Germany). The infected macrophage percentage and 
the number of amastigotes per 100 macrophages were evaluated by counting 200 macrophages using 
an optical microscope (Nikon Eclipse E400, Y-THM, and Y-THR, Chiyoda-ku, Tokyo, Japan). The 
experiment was performed three times in duplicate wells and results are presented as EC50 mean ± 
SD. The selectivity index (SI) was calculated as the ratio between cytotoxicity (EC50) against peritoneal 
macrophages and activity (EC50) against Leishmania amastigotes. 
Pharmaceutics 2019, 11, 607 5 of 19 
2.8. Preparation and Physicochemical Characterization of DAP Formulations  
To obtain the O/W DAP cream, 15 g of oily phase containing cetyl alcohol, stearic acid, solid 
paraffin, liquid paraffin, glyceryl monostearate, and white vaseline (Table 2) were melted in a mortar 
that was heated in a water bath at 70 °C. Then, water (35 g) was added to the oily phase under 
agitation with a pistil until the mixture was cooled. Finally, DAP (10% w/w) was incorporated as a 
micronized powder. The formulation was stored and protected from light in a plastic container at 
room temperature. This cream composition was chosen because PM (15% w/v) solubilized in this 
vehicle was used as an effective treatment in a CL mice model [15].  
Table 2. Composition of the two blank formulations evaluated in this study. 
Phase 
Percentage composition (w/v) 
O/W cream PLE 
Oil Phase 
Cetyl alcohol, 3.9% 
Medium chain triglycerides (MCT, Miglyol 810®), 20.6% 
Soybean lecithin (Lipoid S100®) 4.4% 
Stearic acid, 6% 
Solid paraffin, 1.5% 
Liquid paraffin, 7.5% 
Glyceryl monoestearate, 6.6% 
White vaseline, 4.5% 
Aqueous phase Purified water, 70% 
Purified water, 58% 
Pluronic F127®, 16% 
On the other hand, to prepare the PLE of DAP, lecithin was dissolved in medium chain 
triglycerides (MCT, Miglyol 810®) in an ultrasonic bath and an aqueous solution of Pluronic F-127® 
was allowed to dissolve overnight at 4 °C. Then, the PLE was prepared on ice by adding the aqueous 
phase slowly to the oily phase at a volume ratio of 2.9:1.1, respectively (Table 2). Afterwards, DAP 
(10% w/v) was dissolved in diethylene glycol monoethyl ether (DEGEE, Transcutol®) and 
immediately incorporated into the emulgel. In this case, the formulation was stored and protected 
from light in a plastic container at room temperature.  
Viscosity measurements of the cream and PLE were carried out at 32 °C using a Haake 
Viscotester 550 rotational viscometer with a SV2 rotor (Karlsruhe, Germany) and equipped with a 
thermostatic bath Thermo Phoenix II (Karlsruhe, Germany). Measures were taken from 0 to 700 1/s. 
Viscosities at 150 1/s were chosen for comparison and are expressed as Pascal per second (Pa.s). The 
pH values of the formulations were measured using a digital pH meter (GPL 21, Crison Instruments, 
Barcelona, Spain). Briefly, 500 mg of the formulations were uniformly dispersed in 50 mL of distilled 
water, and afterwards pH values were determined. The spreadability tests were carried out using the 
parallel plate method with modifications [16]. First, 100 mg of the cream and PLE were placed within 
a circle of 1 cm diameter premarked on a glass plate, over which a second glass plate was placed. A 
10 g weight was allowed to rest on the upper glass plate for 5 min. The increase in the diameter due 
to spreading was noted. All experiments were carried out in triplicate. Organoleptic characteristics 
of the formulations were recorded in terms of odor, color, texture, consistency, and external 
appearance. Formulations were also investigated by optical microscopy using a Leica DMD 108 
(Leica Microsystems, Wetzlar, Germany). Measurements were performed either directly or at a 1:10 
distilled water dilution just after formulation at a 40× magnification. 
2.9. Stability Studies 
The stability assessment of DAP formulations was carried out over a 60 day period of storage at 
three different temperatures: 4, 25, and 40  °C. On days 15, 30, 45, and 60, pH, spreadability, 
organoleptic properties, phase separation, drug precipitation, and gravitational stability were 
evaluated and compared with the initial parameters. For the gravitational stability test, preparations 
were centrifuged at 25 °C and 2700 g for 30 min to assess accelerated deterioration [17].  
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2.10. Preparation of Pig Ear Skin  
Skin tissues were obtained from domestic pig ears in a local slaughterhouse. Ears were taken 
from the animals and transported to the laboratory within a maximum of 2–3 h. After washing with 
deionized water, the outer region of the ear was excised with a scalpel and sectioned at a thickness 
of ca. 1 mm using a dermatome (Aesculap GA 630, Tuttlingen, Germany). Then, skins were stored in 
Parafilm® (Bemis, Neenah, WI, USA) at −20 °C for no longer than two months. Studies were carried 
out with intact skin (IS) and damaged skin (without stratum corneum (SC) or epidermis). Before the 
experiments, the skin was allowed to thaw at room temperature in PBS for 30 min. For damaged skin, 
a tape stripping procedure was performed. Adhesive tape (Scotch Transparent Tape 600, 3M, St. Paul, 
MN, USA) was pressed onto the skin and then removed with one quick movement. To determine the 
number of adhesive applications required to eliminate the SC, 0, 15, 30, and 60 pieces of tape were 
applied. After that, samples were staining with Mayer’s hemalum (Merck Darmstadt, Germany) and 
analyzed under a microscope (Olympus BH2, Hamburg, Germany). It was observed that 30 pieces of 
adhesive tape were necessary to remove all of the SC (taped tripped, TS) [18]. In the studies with 
dermal membranes (DM, without epidermis), full-thickness skin was immersed in water at 60 °C for 
45 s to separate the epidermal layer [18].  
2.11. In Vitro Permeation and Penetration Studies 
Permeation studies using Franz diffusion cells were carried out on a MicroettePlusTM apparatus 
(Hanson Research Corp., Chatsworth, CA, USA). Transcutaneous diffusion was assessed according 
to OECD guideline 428 [19]. The Franz cell receptor compartments (4 mL) were filled with 30 mM 
PBS and methanol (70:30) to ensure that sink conditions were maintained over the time course of the 
experiment. Moreover, the receptor medium was homogenised by magnetic stirring (400 rpm) and 
maintained at 32 ± 1 °C. Skin biopsies were placed horizontally between the donor and the receptor 
compartments with the SC, epidermis or dermis side up, ensuring their contact with the receptor 
medium. The whole device was then fixed with a clamp. All Franz diffusion cell experiments were 
conducted under infinite doses conditions: 500 mg of the two DAP formulations (cream and PLE) 
were deposited on 1.74 cm2 of skin in the donor compartment. The punch areas were devoid of visible 
structural changes (scratches, erosion, or scars); as such, skin damage could affect the diffusion and 
metabolism of the tested compound. The drug diffusion kinetic was evaluated by manual sampling 
1 mL aliquots of the receptor fluid at the following predetermined times: 0, 0.5, 1, 2, 3, 4, 6, 8, and 24 
h. Each withdrawn aliquot was replaced with an equal volume of receptor phase. Franz cell blank 
experiments were conducted with the formulations without drugs. At the end of the experiment, the 
excess formulation was removed and the skin pieces were washed with deionized water and stored 
at −80 °C until analysis. Skin sections were pretreated with 10 µL of proteinase K (10 mg/mL, Sigma) 
in 200 µL of Tris-Ethylenediaminetetraacetic acid (TE) buffer for 12 h at 56 °C. Then, the treated 
samples were vortexed, mixed with 800 µL of acetonitrile, and filtered. Next, 500 µL of the filtrate 
was evaporated and resolved in 500 µL of mobile phase. The corresponding calibrators were 
prepared, treating DAP in the same way as skin samples. DAP was quantified by HPLC-UV. Analysis 
was carried out in a 1200 series LC (Agilent Technologies, Waldbronn, Germany) with a diode-array 
detector set at 295 nm. The chromatographic system was equipped with a C18 column (150 mm × 4.6 
mm, 5 µm particle size; Phenomenex, CA, USA) operating at 40 °C. The mobile phase, pumped at 1 
mL/min, was a mixture of methanol and PBS 0.03 M (30:70) in isocratic conditions. For the 
quantification, calibration curves were made in the following ranges: 0.01–50 µg/mL (for reception 
medium samples) and 2.5–98 µg/mL for skin samples. All of the calibration curves met the previously 
established performance criteria (R2 > 0.999, slopes significantly different from 0 and a relative error 
(in %) for calibrators <15%). Samples from the receptor compartment were directly injected after 
appropriate dilution in the mobile phase (PBS/methanol, 70:30). The corresponding standards for 
calibration were also prepared in the mobile phase. The percentage of DAP recovery from skin 
samples was 100.2 ± 2.2%, which is largely within the 90–110% range that is considered acceptable. 
Results are expressed as mean ± SD (n = 6 for each skin model), performed for at least two 
independent experiments.  
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The flux of drug permeated (Jss, g/cm2·h) was calculated from the slope of the steady-state 
portion of the permeation profile by linear regression analysis [20]. The lag time (h) was calculated 
from the back extrapolation of the steady-state portion of the graph. The permeability coefficient (Kp, 
cm/h) was also calculated as Jss/Cdonor, with Cdonor being the drug concentration applied to the 
skin surface. 
2.12. In Vivo Efficacy Studies of DAP Formulations in L. major-infected BALB/c Mice 
Animals were infected by subcutaneous inoculation of 103 or 105 infective metacyclic 
promastigotes of L. major in the ear or the base of the tail, respectively. Lesions took different times 
to reach a similar size, so mice were incorporated into the efficacy assay at different times. After 4–6 
weeks, lesions of measurable size (average surface of 10 mm2 or volume 5 mm3) had developed in 
mice and topical treatments were initiated. Three different groups (n = 8) were evaluated in the tail 
model of infection: (i) untreated infected mice; (ii) mice treated with DAP cream; and (iii) mice treated 
with DAP–PLE. Moreover, two groups were evaluated in the ear model (n = 5): i) untreated infected 
mice; and ii) mice treated with DAP–PLE. Topical treatments were administered twice daily with 50 
mg of DAP cream or DAP–PLE for a period of 30 days. Once treatments were finished, animals were 
kept for 3 days before sacrifice. Lesions were measured every 3 days with a digital caliper. A 
paromomycin cream (PMN, 15% w/w) was used as positive control. Final results were expressed as 
the mean of the lesion diameter or volume (mm2 or mm3) ± SD. The parasitic load was quantified by 
PCR and results are expressed as the median. For this purpose, skin fragments from lesions as well 
as spleen, liver, and popliteal lymph nodes of infective mice were aseptically removed and conserved 
at –80 °C until quantification. 
2.13. Blood Sampling 
At treatment points coinciding with blood sampling (days 0, 1, 2, 3, 12, and 18), samples were 
drawn prior to the morning application of topical DAP. Plasma concentrations of DAP were assayed 
using HPLC/UV at the same conditions previously described. The mobile phase was a mixture of 
methanol and PBS 0.03 M at a ratio of 20:80 in isocratic conditions. For the quantification, calibration 
curves were made in the range of 1–40 µg/mL. The percentage of DAP recovery from blood was 51.2 
± 3.4%. Finally, the determination of hemoglobin and hematocrit was performed in total blood using 
a ABX pentra 60 hematology system. Results are expressed as mean ± SD (n = 6). 
2.14. Iron Determination in Spleens  
Representative samples of spleen were weighed and later dried in an oven (70 °C) to a constant 
weight. An accurately weighed sample of dried spleen (100–150 mg) was digested with 6 mL sub-
boiling nitric acid (distilled from nitric acid 65%, Merck, Darmstadt, Germany) in a closed acid 
decomposition microwave system (Ethos Plus, Millestone s.r.l., Sorisole, Italy). Digested samples 
were then made up to 25 mL with ultrapure deionized water. Iron measurements were performed by 
flame atomic absorption spectrophotometry (Perkin–Elmer Analyst 800, Norwalk, CT, USA) at 248.3 
nm, using a hollow cathode lamp operated at 30 mA and a bandwidth of 0.2 nm. A high-sensitivity 
nebulizer and an air/acetylene flame with oxidant and fuel flow amounts of 17.0 and 2.0 mL min−1, 
respectively, were used. Digested samples solutions were analyzed in triplicate. Iron detection limit 
(LOD) was set at three times the standard deviation of the blank reagent and corresponded to 0.11 
mg/g (n = 6), expressed in terms of dry weight. A recovery study was carried out from the spleen 
samples to check the accuracy of the analytical method (98.2–103.9%; n = 6). 
2.15. qRT-PCR 
Parasite DNA from lesion tissue, spleen, liver, and popliteal lymph nodes was obtained 
following the Genomic DNA tissue protocol of Nucleospin (NucleoSpin Tissue Macherey Nagel). 
After DNA obtention, concentrations were measured in a Nanodrop (ND-1000 spectrophotometer, 
Thermo Scientific, Waltham, MA, USA). One nanogram of DNA was used to quantify Leishmania with 
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a qRT-PCR system (Bio-Rad, Hercules, CA, USA) by using iQ SYBR Green supermix (Bio-Rad, 
Hercules, CA, USA) and primers for minicircle kinetoplastic DNA (kDNA) of L. major. The number 
of kDNA copies was determined by extrapolation from the cycle threshold of each sample on a 
standard curve of known concentration, which gave the number of parasites × 104. The standard was 
generated by insertion of the Leishmania amplicon in a pCR2.1-TOPO vector (TOPO TA cloning kit; 
Invitrogen, Carlsbad, CA, USA). 
2.16. Statistical Analysis 
Statistical significance was analyzed using Prism 6.0 software. Differences were tested using the 
Mann–Whitney test for two groups comparison or the one-way ANOVA with Dunnett´s post hoc test 
for multiple comparison (in vivo efficacy study), with * p < 0.05; ** p < 0.01; *** p < 0.001. 
3. Results 
3.1. In Vitro Antileishmanial Activity and Citotoxicity Studies 
Table 3 shows the antileishmanial activity of DAP. In L. major promastigotes, DAP activity was 
1.6-fold higher than in L. braziliensis promastigotes (EC50 at 92 µM vs. 147 µM). Moreover, it showed 
low toxicity against peritoneal macrophages, fibroflasts, and keratinocytes. We evaluated the 
cytotoxicity of DAP in these cells, as they are the most frequently found type of skin cells and are also 
involved in skin repair and wound healing. In fact, the lowest toxicity was found in HaCaT cells (EC50 
at 3186 µM) followed by peritoneal macrophages (1490 µM) and 3T3 fibroblasts (433 µM) after 48 h 
of treatment. When DAP was tested against intracellular amastigotes, the activity in L. major 
amastigotes was similar to than in promastigotes (EC50 at 92 µM vs. 94 µM). However, in the case of 
L. braziliensis, DAP was 2.7-fold more effective in amastigotes than in promastigotes. Moreover, the 
number of L. major and L. braziliensis amastigotes decreased at increasing doses (Figure 1). At 500 µM 
of DAP, a reduction of 71% was found in L. braziliensis, whereas a 45% decrease was obtained for L. 
major. At the lowest dose tested (25 µM), DAP showed 2-fold more activity in L. braziliensis than in L. 
major (9.1 µM vs. 20 µM, respectively). Finally, this compound was more selective in killing 
intracellular parasites than macrophages, showing selectivity index values higher than 15 (Table 3).  
Table 3. In vitro activity on L. major and L. braziliensis promastigotes and amastigotes, and toxicity in 
mouse peritoneal macrophages, fibroblasts, and keratinocytes after 48 h of treatment with DAP. 
EC50 (µM) 
L. major L. braziliensis Peritoneal 
Macrophages 
3T3 
Fibroblasts 
HaCaT Keratinocytes 
Promastigotes Amastigotes Promastigotes Amastigotes 
91.8 ± 28.4 93.7 ± 11.4 147.2 ± 42.6 54.5 ± 8.3 1490 ± 300 433 ± 109 3186 ± 208 
%
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Figure 1. Percentage of L. major or L. braziliensis amastigote reduction at different concentrations of 
DAP after 48 h of treatment. Results are expressed as mean ± SD (n = 6). 
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3.2. Physicochemical Characterization of the DAP Formulations 
The formulations without or containing DAP were characterised in terms of viscosity, 
spreadability, and pH, and results are presented in Table 4. It can be observed that when DAP was 
incorporated in the cream, the viscosity and the pH were similar to those in the blank cream (2.46 vs. 
2.43 Pa.s and pH 6.52 vs. 6.57). However, the spreadability was slightly decreased (0.85 vs. 0.6 cm). 
In the case of the PLE formulation, the viscosity was lower when DAP was incorporated in the PLE 
(3.31 vs. 2.21 Pa.s). In contrast, the spreadability value was 2-fold higher than in the PLE without DAP 
(1.77 vs. 0.92 cm). Moreover, DAP–PLE showed 3-fold higher spreadability than DAP cream (1.77 vs. 
0.6 cm). The spreadability plays an important role in patient compliance and allows uniform 
application to the skin. According to spreadability data, the PLE DAP formulation was more 
comfortable and easier to apply over CL diseased skin than the conventional O/W cream.  
Comparing the pH values, the PLE formulations showed lower pH than the cream, but all of 
them were within the acceptable limits for topical application (between pH 4.8 and 6.6). Concerning 
the organoleptic characteristics of the DAP cream, it was odorless, had an opaque white color with 
high consistency, and had no signs of exudation. Moreover, DAP–PLE had a noticeable odor, 
appeared as opaque light beige, was greasy, soft, and easily spreadable without any visible signs of 
phase separation or drug precipitation.  
Table 4. Physicochemical characteristics of the cream and PLE formulations (mean ± SD, n = 3). 
Formulation Viscosity (Pa.s) Spreadability (cm) pH 
Cream 2.46 ± 0.61 0.85 ± 0.14 6.52 ± 0.01 
DAP cream 2.43 ± 0.55 0.62 ± 0.07 6.57 ± 0.04 
PLE 3.31 ± 0.13 0.92 ± 0.17 4.97 ± 0.19 
DAP–PLE 2.21 ± 0.04 1.77 ± 0.06 4.84 ± 0.04 
Regarding microscope images, plain (data not shown) or DAP (Figure 2b) cream showed 
aggregation of the inner oily vesicles, whose sizes ranged from 20 to 60 µm. The particles of 
micronized DAP (light brown color) dispersed in the O/W cream had sizes ranged from 10 to 60 µm, 
similar to what was observed in water (Figure 2a). On the other hand, DAP, solubilized in DEGEE, 
was easily precipitated when water was added (Figure 2c) in the form of big and long crystals 
(between 100 and 350 µm, approximately). Although no visible signs of drug precipitation were 
found in DAP–PLE, microphotographs (Figure 2d arrows) revealed some DAP precipitation, 
consistent with solubilization until saturation level. However, these crystals were smaller than in 
Figure 2c, with sizes around 40–80 µm. Finally, microscope images revealed PLE as an O/W emulgel. 
The oily vesicles of MCT with a mean diameter of 35 µm would be stabilized with lecithin and 
Pluronic F127® gelled aqueous phase.  
 
Figure 2. Optical photomicrographs at 40x magnification of (a) micronized DAP in water, (b) O/W 
cream containing DAP and diluted 1:10, (c) DAP in diethylene glycol monoethyl ether (DEGEE)/water 
(1:10 v/v), and (d) DAP–PLE at a 1:10 dilution. Scale bar = 500 µm. Arrows represent DAP. 
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Regarding stability studies, DAP cream was shown to be stable during the evaluation time at 
the three different storage temperatures. Only pH values seemed to increase slightly compared to the 
initial formulations (Table S1). However, DAP–PLE was not stable over time. Although at 4 °C all 
parameters, with the exception of noticeable drug precipitation (only 15 days), were maintained for 
60 days, at 25 and 40 °C, there was a clear degradation over time. This lack of stability was observed 
not only in color, pH, and spreadability, but also in organoleptic properties, phase separation, and 
drug precipitation. After 60 days at 25 and 40 °C, pH decreased (from pH 4.84 to 3.67 and 3.55, 
respectively). Besides, spreadability increased 1.8-fold after 25 °C storage, probably due to 
exhudation phenomenon. Moreover, none of the formulations of the DAP–PLE overcame the 
gravitational stability test (Table S2). 
3.3. In Vitro Permeation and Penetration Studies in Pig Ear Skin 
Skin CL lesions can vary widely across the infecting Leishmania strains, from small dry lesions 
to large ulcers or even keratolytic nodules. As an attempt to mimic the conditions of skin lesions 
observed in CL, the permeation studies were conducted in three skin models: IS, TS (removal of the 
SC, which was used to mimic the damaged skin), and DM (skin without epidermis). DM has been 
considered as a good model for ulcerated skin lesions [18,21,22]. The results are summarized in Table 
5 and Figure 3. As was expected, it was determined that there were higher cumulative amounts of 
DAP in the receptor compartment 24 h after dosing in DM than in TS (around 20-times higher) and 
IS (around 100-times higher) for both DAP cream and PLE. Regarding the flux, similar and low Jss 
were obtained for PLE and cream in IS (0.05 vs. 0.06 µg/cm2/h). These values increased with the use 
of TS only after application of PLE (0.32 µg/cm2/h). Finally, they greatly increased in DM and similarly 
increased for both DAP cream and DAP–PLE (3.96 vs. 4.22 µg/cm2/h). In relation to lag times, similar 
results were obtained from the two formulations, with values ranging from 2 to 3 h.  
In addition permeated drugs, the amount of DAP retained in the skin after 24 h was also 
analyzed (Table 5). The cream formulation presented higher capacity to retain the drug in the skin 
than the PLE. In IS and TS skin, the amount of DAP deposited was around 2-fold higher for the DAP 
cream than for the DAP–PLE. However, it was 4-fold higher when DM were used (0.68 and 2.87 µg 
of DAP/mg skin quantified in DM, for DAP-PLE and DAP cream, respectively).  
Table 5. In vitro permeation and penetration values obtained for DAP formulations across pig ear 
skin after 24 h. 
Formulation Jss  (μg/cm2/h) 
Kp  
(cm/h) 
Lag Time 
(h) Cumulative Permeated DAP (µg/cm
2) DAP in Skin (μg/mg)  
DAP–PLE 
IS 0.05 ± 0.02 5.13·10-7 3 0.73 ± 0.57 0.10 ± 0.07 
TS 0.32 ± 0.16 3.24·10-6 3 5.22 ± 2.55 0.14 ± 0.03 
DM 3.89 ± 1.71 3.89·10-5 2 116.47 ± 37.65 0.68 ± 0.54 
DAP Cream 
IS 0.06 ± 0.01 6.13·10-7  3 1.29 ± 0.19 0.21 ± 0.02 
TS 0.11± 0.09 1.14·10-6 3 1.42 ± 1.04 0.28 ± 0.09 
DM 3.96 ± 1.43 3.96·10-5 2 134.75 ± 51.47 2.87 ± 0.95 
Abbreviations: IS, intact skin; TS, tape stripped; DM, dermal membranes; Jss, steady-state flux; Kp, 
permeability constant. 
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Figure 3. Amount of DAP permeated in vitro for the cream and PLE in the three different skin models 
evaluated using pig ear skin after 24 h of application. Abbreviations: IS, intact skin, TS, tape stripped; 
DM, dermal membranes. 
3.4. Evaluation of Efficacy in L. major-infected BALB/c Mice: Tail and Ear Models 
To evaluate the in vivo efficacy of DAP, BALB/c mice were infected with L. major metacyclic 
promastigotes in the base of the tail. Once lesion size increased to 10 mm2, topical application of the 
cream and PLE started. Mice showed a continuous increase in lesion size (Figure 4a,b). In fact, mice 
treated with DAP cream and DAP–PLE exhibited a faster increment in lesions than non-treated mice. 
After 18 days of treatment, the topical administration of PLE was stopped because lesion sizes were 
2.5-fold higher than in the control group (125 mm2 and 50 mm2, respectively, p < 0.05). 
 
Figure 4. In vivo efficacy study in the tail model. (a,b) Lesion progression during the treatment with 
DAP cream or DAP–PLE. PM cream was used as positive control. (c) Parasite burden in skin, lymph 
node (LN), liver, and spleen after 18 days (PLE) or 30 days (cream) of treatment compared with a 30 
day treatment of PMN cream. Results are expressed as the median (n = 8). Note: * p < 0.05, ** p < 0.01, 
and *** p < 0.001). 
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After 30 days DAP cream treatment, lesions had sizes around 186 mm2 compared to 125 mm2 for 
control mice (p < 0.05) (Figure 4a,b). Furthermore, the amount of DAP quantified in the lesions treated 
with DAP cream was 9.6 ± 8.5 µg of DAP/mg of skin, which is 0.5 ± 0.4 mg/mice. Finally, parasite 
burden in skin, lymph node, and liver was similar in mice treated with the cream than in non-treated 
mice. However, the number of parasites found in the spleen was significantly lower (p < 0.05) (Figure 
4c). Moreover, when DAP–PLE was administered, parasite burden in lymph node (p < 0.05) and 
spleen (p < 0.001) was also significantly reduced.  
On the other hand, in the ear model, treatment with DAP–PLE was started when lesion sizes 
reached 5 mm3 (Figure 5a,b). At day 10, treatment was stopped as the volume in PLE-treated ears 
was 2.6-fold higher than in the control (24 mm3 vs. 9 mm3, respectively). Moreover, skin irritation, 
peeling, and hair loss were found in mice treated with DAP–PLE (Figure 5b). Parasite burden 
quantified in skin was similar to that in the control. However, parasites quantified in spleen were 
also reduced, as in the tail model (Figure 5c).  
 
Figure 5. In vivo efficacy study in the ear model. (a,b) Lesion progression during the 10 day treatment 
with DAP–PLE. (c) Skin sections stained with H&E after treatment with PLE. Images are taken at 10x 
magnification; Scale bar = 300 µm. (d) Parasite burden in skin and spleen after 10 days of treatment. 
Results are expressed as the median (n = 5). 
3.5. Plasma Levels, Hematologic Effect, and Iron Content in Spleen after DAP Treatment 
Plasma concentrations of DAP were detected 8 h after the first application of DAP cream, with 
a mean value of 23 µg/mL. After 24 h, this concentration was maintained (21 µg/mL). However, it 
decreased slightly throughout the days. Finally, 13 µg/mL of the drug was determined at day 18 
(Figure 6). Furthermore, as is shown in Table 6, after DAP treatment significantly lower levels of 
either hemoglobin (12 vs. 17 g/dL, p < 0.01) or hematocrit (39 vs. 51%, p < 0.01) were detected 
compared to control untreated mice. Besides, at the end of treatment, a significantly higher amount 
of iron was quantified in spleen (2.9 vs. 3.5 mg/g, p < 0.05). H&E staining of spleen revealed no signs 
of toxicity after DAP treatment. 
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Figure 6. DAP plasma concentration as function of time. Blood was extracted 24 h after the last daily 
administration. Results are expressed as the mean ± SD (n = 6). 
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Table 6. Hemoglobin and hematocrit levels after 18 days of DAP cream treatment. Iron accumulation 
in spleen at the end of treatment (n = 8). (* p < 0.05 and ** p < 0.01). 
Group HGB (g/dL) HCT (%) Fe Accumulation in Spleen (mg/g) 
Control 17.1 ± 0.5 51.3 ± 1.9 2.89 ± 0.50 
Cream 12.4 ± 1.4 ** 38.9 ± 5.1 ** 3.54 ± 0.50 * 
Abbreviations: HGB, hemoglobin; HCT, hematocrit. 
4. Discussion 
DAP has been studied for several dermatological diseases, such as leprosy, dermatitis 
herpetiformis, or epidermolysis, based on its anti-inflammatory (mostly as inhibitor of neutrophil 
infiltration) and antimicrobial properties [7]. However, its use after oral administration is widely 
limited by hematological toxic effects. Topical administration allow its local effects, while avoiding 
systemic toxicity. At present, a gel formulation of micronized DAP (Aczone®) is authorized in some 
countries for the treatment of acne, with a good security profile [23].  
Because topical therapy is easy and usually painless, it is an attractive first-line option for the 
treatment of localized cutaneous leishmaniasis (LCL). In this work, we addressed the preparation of 
topical formulations for DAP and the assessment of their efficacy in mice with CL lesions by the 
topical route.  
CL topical therapy represents an enormous challenge, as the target (parasites that harbour 
macrophages) is localized in the dermis, the deepest skin layer. The accumulation of drugs in this 
layer is problematic because it has to contend firstly with the SC barrier, and secondly with a rapid 
clearance to systemic circulation. Moreover, the amount of drug accumulated in the dermis should 
be higher than a certain threshold of concentration (>IC50) and be retained there during the time-to-
kill, a parameter that has not been properly considered for antileishmanial agents. It is well-known 
that drug penetration and permeation into and through the skin is a passive diffusion process, and 
drug concentration progressively decreases from upper to lower layers [24]. 
As an advantage in CL lesions, the SC is seriously damaged and this circumstance broadens the 
optimal physicochemical properties of drugs (MW < 500 Da and LogP 1–4), with the possibility to 
penetrate into the skin to molecules with MW higher than 500 Da and either more hydrophilic or 
hydrophobic properties. As a limitation, Leishmania spp. infection is associated with local 
inflammation, increase of blood flow, and skin clearance [25]. On one hand, only interactions with 
dermal components allow the formation of a reservoir in the dermis [26]. On the other hand, only 
free drugs are active to exert their action [27].  
In order to design a formulation of DAP for its topical application, we initially predicted its flux 
by application of the Potts–Guy equation [28], considering a saturated aqueous solution (0.380 mg/L), 
and the flux value obtained was 0.102 µg/cm2/h. We also determined a value of antileishmanial 
activity in vitro against L. major infected macrophages of 23.2 µg/mL (IC50 = 93.7 µM, Table 3). 
Although the permeability is higher through damaged skin [29], a formulation able to enhance drug 
penetration is needed. A cut-off value has been established of 1 for the ratio flux/in vitro potency 
(efficacy index, EI) as a guide element for separating effective and non-effective topical molecules 
[30–32]. This approach is more or less useful for predicting the efficacy of groups of therapeutic agents 
with targets in the different skin layers, such as antifungal (viable epidermis) or corticosteroid 
treatments (epidermis and dermis) [33]. According to this criteria, DAP would not be a good topical 
candidate (EI of 0.0044). However, we decided to test it as we did not observe a correlation between 
the theoretical EI of some antileishmanial drugs and their topical CL efficacy reported in mice [34–
36] (see Table 7). Additionally, regarding topical drugs assayed in CL, PM, the only one with efficacy, 
showed the lowest theoretical flux [6]. On the contrary, sitamaquine (SIT) had a very high flux, 
although it was not effective [34].  
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Table 7. Comparison between the theoretical efficacy index (EI), calculated from the flux (Jss) and the 
EC50 value ratio, and the in vivo efficacy in mice for different antileishmanial drugs administered 
topically. 
Drug 
Kp 
(cm/h) 
Ssat 
(mg/L) 
Jtheor 
(µg/cm2/h) EC50 EI Efficacy  
AmB 1.63 × 10−8 0.75 1.23 × 10−5 0.1 0.0001 NE  [6] 
DAP 2.71 × 10−4 0.38 0.103 24.8 0.0044 NE  
SIT 4.96 × 10−3 50 247.95 0.93 266.02 NE  [34] 
BUR 0.045 0.03 1.35 0.49 2.765 NE [35] 
MIL 2.48 × 10−4 0.22 0.05 0.81 0.067 E* [36] 
PM 4.17 × 10−13 50 2.08 × 10−8 123.4 1.689 × 10−10 E [6] 
Abbreviations: AmB, amphotericin B; DAP, dapsone; SIT, sitamaquine; BUR, buparvaquone; MIL, 
mitelfosine; PM, paromomycin; Kp, permeability constant; Ssat, saturated aqueous solution; Jtheor, 
theoretical flux; EI, efficacy index; NE, no efficacy; E, efficacy; E*, there are two studies published: one 
effective and the other not effective. 
In order to enhance DAP permeability, we proposed a pluronic lecithin organogel [37]. We chose 
this type of formulation because of its ability to enhance the permeability of hydrophilic and 
hydrophobic drugs, either by its drug solubilization effect or by the interaction of lecithin or the oily 
phase with the skin, producing its disorganization. Our modus operandi was to use a ratio between 
the aqueous and oily phase similar to the one currently described in pharmaceutical compounds, 
with the exception that the most common organic phase, isopropyl palmitate, was replaced by MCT. 
However, taking into account the composition of the selected formulation (Table 2), we should 
highlight that it was not an organogel but an emulgel because of the greater amount of aqueous phase 
compared with the oil content. The vesicles of the oily phase would be stabilized by lecithin and 
Pluronic F127®, as observed in the optical photomicrographs (Figure 2). In fact, the term Pluronic 
lecithin organogel comprises different types of lecithin-based nanostructured gels, whose molecular 
organization has not been deeply investigated [37].  
DAP was solubilized in DEGEE until saturation level (0.5 mg/mL) for its incorporation into PLE 
in solution and at its maximum thermodynamic activity [38]. According to Fick’s diffusion law that 
governs the process of penetration of drugs through the skin, only the amount of drug in solution is 
taken into account in the process. Although drug formulation can increase the amount of the 
solubilized drug, its flux through the skin is enhanced only if the saturation limit is achieved. Far 
from the saturation level, the drug could have less tendency to leave the formulation [38,39]. The 
presence of small particles of DAP would confirm we achieved its saturation level (see Figure 2). On 
the other hand, DEGEE has been described as a skin penetration modifier. It tends to enhance the 
permeant skin solubility, resulting in either increased accumulation of the drug in the SC 
(hydrophobic drugs) or increased permeation [40].  
Next, we addressed in vitro permeability studies with pig ear skin at infinite dose applications. 
The PLE was compared with an O/W cream (composition summarized in Table 2), in which DAP 
was incorporated as a micronized powder at the same final concentration (10% w/v). This vehicle was 
the same as that used for the topical administration of PM (used as control for effective treatment) 
[15]. A priori, a similar and maximal thermodynamic activity of 1 can be assumed for both types of 
formulations of DAP, either PLE or O/W cream, because of the drug solubilization at its saturation 
level in each one, although the amount of solubilized drug could be greatly different. The use of 
suspensions in topical formulations has several advantages, such as sustained release and prolonged 
levels of drug in the skin layers, while avoiding toxic plasmatic levels of the drugs [41]. However, 
they may pose problems related to stability and feeling. In detail, Aczone® (the commercialized 
trademark of DAP) consists of a suspension of the drug in a hydrogel with 25% DEGEE. In this 
formulation (at 5% w/v of drug), one-third of the drug is dissolved and two-thirds are suspended as 
small particles. DAP particles can accumulate in the pilosebaceous unit, which is very suitable for the 
treatment of acne [40].  
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PLE and DAPs cream showed similar skin permeation profiles, as shown in Figure 3 and 
summarized in Table 5. Flux was very low in healthy skin—lower than the theoretical value 
calculated from the Potts–Guy equation from saturated aqueous solution. As expected [29], the 
permeation of DAP was slightly enhanced when the SC was partially removed by tape stripping. 
Additionally, it only increased when SC along with the viable epidermis were removed (in DM). The 
accumulation of the drug in the skin was also higher in DM (see Table 5) than in the other skin 
conditions and reached the same absolute values as quantified in the receptor compartment. Results 
indicated that the epidermis was the major barrier for DAP permeation. On the other hand, the free 
diffusion between dermis and receptor compartments would allow the use of the flux parameter as 
a predictor of efficacy in DAP topical formulations, because the concentration of the drug in this skin 
layer is, apparently, the key to its activity [34,42]. The similar and low fluxes (Table 5) obtained from 
both types of formulations in all skin conditions suggest a possible precipitation of DAP onto the skin 
upon DGEE absorption from PLE, as previously reported [41]. 
Although we obtained very low flux values, we decided to evaluate the efficacy of the 
formulations in BALB/c mice infected with L. major, applying a high dose of the drug (500 
mg/kg/day). DAP was non-effective and even aggravated the size and appearance of the lesions in 
the two mice models evaluated (Figure 4a,b, and Figure 5a,b), especially after PLE application. The 
amount of DAP accumulated in the skin after 30 days of treatment had a mean value of 0.5 ± 04 
mg/mice, around 5% of the daily dose (10 mg). Furthermore, the plasma levels of the drug (80 
µg/mice, around 1% of the daily dose) were much higher than what has been reported after chronic 
administration of 150–500 mg/kg/day in healthy mice [43]. This could probably be due to the higher 
permeability of skin with CL lesions [44], because the area of treatment was similar. We have had 
difficulty finding information about DAP toxic levels after administration in rodents, as DAP 
hydroxylamine (DHA), the main metabolite responsible for its side effects, is not produced in mice 
[45]. Due to this fact, mice are not considered a good model for investigating systemic toxicity of 
DAP. 
Clinical signs of DAP effects in skin (desquamation and hair loss) were more evident after 
application of PLE, either in the base of the tails or in the ears (see Figures 4b,5b). We did not evaluate 
the effect of unloaded PLE, but PLE with IPP as an oil phase had a good safety profile. On the other 
hand, DEGEE is also considered safe until 40% and DAP–PLE contained a lower percentage (20%). 
However, the addition of DEGEE to the PLE could produce a higher interaction with the skin and 
produce irritancy. On the other hand, anemia and associated increase of iron content in the spleen 
were detected (Table 6). We suggest that the accumulation of iron in the spleen could be responsible 
for the partial parasite clearance in this organ (p < 0.001). The effect played by iron metabolism in the 
interaction between host and parasite is being investigated as a potential leishmanicidal strategy. 
Both macrophages and parasites absolutely need iron to survive and their levels must be delicately 
regulated to support macrophagic killing mechanisms during infection. While some studies showed 
the importance of iron deprivation in decreasing susceptibility to Leishmania infection by limiting the 
amount of iron available to the parasite, others indicated that it may favour the proliferation of 
parasites by damaging the immune system [46]. On the other hand, iron-loaded BALB/c mice infected 
with L. major showed reduced parasite burden in organs compared to non-treated mice [47]. Bisti et 
al. demonstrated that iron not only contributed to diminished infection but also to protecting mice 
when animals were infected with low doses of parasites. 
These in vivo results of DAP skin delivery are partially in agreement with the in vitro permeation 
studies performed in IS and TS skin models, in which around 80% of the drug amount that left the 
formulation remained in the skin and 20% remained in the RC, but not in accordance with the results 
obtained in DM. Although the skin is seriously damaged when containing CL lesions, these are not 
really ulcers that expose the dermis, but necrotic and granulomatous tissue that could pose a barrier 
for permeation of drugs [48]. However, the total amount of DAP that was released from the 
formulation was higher than that observed in the in vitro experiments (20 µg DAP/mg skin in vivo 
vs. a maximum of 1 µg/mg skin in ex vivo studies). The permeability of mice skin is generally higher 
than pig ear or human skin and is markedly increased in CL lesions. Furthermore, the ex vivo 
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permeability studies depend only on the process of diffusion, whereas in vivo factors such as blood 
flow or plasma-binding proteins can accelerate or retard the skin clearance [26]. Blood flow is 
increased in CL lesions because of associated inflammation [25]. Actually, the efficacy results for PM 
and inefficacy of buparvaquone (BUR) in CL-infected mice were well correlated with the EI 
calculated using ex vivo experimental flux values obtained with infected mouse skin [44]. 
Despite systemic toxic levels, it seems that the amount of DAP retained in the skin (20 µg/mg 
skin) was not enough for parasite clearance, probably due to its accumulation in other skin layers 
and not in the dermis, according to the ex vivo permeability studies for the models of IS or TS. On the 
other hand, the plasma-binding protein described for DAP was around 70% [49], and as only the free 
drug is effective, this could be below the threshold of therapeutic efficacy. This estimation also 
considers that drug detected in the blood was through the dermis (the skin target), which only 
represented 1% of that total administered drug. There is a great interest in finding any correlation 
between pharmacokinetic (PK) or pharmacodynamics (PD) parameters and antimicrobial activities, 
in order to provide a rational dosing regimen to control the development and spread of resistance. 
Measures of free drug exposure over a 24 h period (fAUC) in relation to the organism minimum 
inhibitory concentration (MIC) are correlative with the antimicrobial efficacy for most antibiotic 
classes, but not for all of them. For example, for β-lactams, maintaining a free drug concentration 
above the MIC of the organism for a portion of the dosing interval has been shown to best predict 
microbiologic efficacy [50]. These types of studies are lacking in antileishmanial therapy, even after 
parenteral administration. Therefore, in topical therapy, the PK/PD considerations are complicated 
by the need for knowledge of drug distribution among different layers of skin and then into the blood. 
A previous study optimized a formulation of DAP in nanoemulsions [51]. The best composition 
achieved a flux value around 100 µg/cm2/h through the porcine epidermis. As we observed systemic 
toxicity upon application of our formulations with much lower flux values, it seems logical to 
suppose even higher toxicity with formulations with higher permeation. In order to enhance the 
safety index of DAP after topical application, a formulation able to modulate its clearance from the 
dermis would be necessary. Formulations able to generate a depot in the SC after their topical 
application have been reported because of their components (i.e., propilenglycol) and could have a 
certain penetration at this skin level [52]. In healthy skin, most of the formulation components cannot 
penetrate the dermis and modify the diffusivity and clearance of drugs from this skin layer. Thus, it 
is necessary for the drug to achieve rapid penetration of the epidermis and dermis (governed by 
formulation and drugs properties) and low clearance from the dermis to the blood circulation (sole 
function of the drug physicochemical properties). However, we should underline that with partial 
removal of the SC, more formulation ingredients will have the chance to penetrate the dermis, and 
perhaps affect the accumulation or clearance of the drug from this skin layer. 
Overall, our study indicated that topical therapy with DAP at a dose of 500 mg/kg/day 
administered for 30 days does not cure CL. Moreover, this schedule of administration produced 
systemic toxicity. Thus, DAP was not a correct choice for the topical therapy of CL, mostly due to 
poor dermal retention and inadequate safety index.  
Supplementary Materials: The following are available online at www.mdpi.com/xxx/s1, Table S1: Stability 
studies for DAP cream over a period of 60 days at different temperatures. Table S2: Stability studies for DAP 
PLE over a period of 60 days at different temperatures.  
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